Proactive Investors - Run By Investors For Investors

Adamis Pharmaceuticals shares skyrocket on news of Novartis distribution deal for anaphylaxis product

The deal is with the Sandoz Inc division is for the Adamis’ Symjepi product
Adamis Pharmaceuticals shares skyrocket on news of Novartis distribution deal for anaphylaxis product
Adamis’ Symjepi product is for the emergency treatment of allergic reactions

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares shot up almost 40% to US$4.45 on Monday after the San Diego-headquartered firm after it announced a distribution and commercialization agreement with drugs giant Novartis Group.

The deal with the latter's Sandoz Inc division is for the  Adamis’ Symjepi product for the emergency treatment of allergic reactions (Type I) including anaphylaxis.

The Symjepi injector is a competitor of Mylan's well-known EpiPen product

Sandoz will distribute and sell the 0.3 and 0.15 mg versions of Symjepi, said Adamis.

"We are very excited about our collaboration with Sandoz," said Dr Dennis J. Carlo, the president and chief executive of Adamis.

"They are among the top pharmaceutical companies in the world and we believe they have the commercial presence and proven track record to maximize the value of Symjepi. 

"We believe the financial terms of this agreement have the potential to bring meaningful recurring revenue to Adamis and we look forward to growing, and possibly expanding, this partnership with Sandoz based on the future success of Symjepi in the market.”

Adamis is a specialty biopharma company, which is focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy.

View full NVS profile View Profile

Novartis Timeline

Related Articles

scientist at petrie dish
May 15 2019
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
Scientist at work
May 28 2019
CaPre, a potent form of Omega-3, has been shown to reduce triglycerides, but also lower 'bad cholesterol' levels, and raise 'good' ones

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use